Of eligible subjects, 45/67 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months

Others 22/67 subjects joined to the study as data contributors, and were entered as controls (CONTR).

Type 1 Diabetes Mellitus

Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 42/65 T1D children

omega-3 supplementation

Vitamin D supplementation

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients (POSEIDON)

Omega-3 and Vitamin D Supplements in Childhood T1D

Omega 3 Long Chain Polyunsaturated Fatty Acids, Enriched Mediterranean Diet and Vitamin D Supplementation in Childhood Type 1 Diabetes: One Year Case-cohort Study

mg/dl; 1 mg/dl:0.05551 mmol/liter; gluco-oxidase colorimetric method (GLUCOFIX, by Menarini Diagnostics, Florence, Italy)

measured through the high-performance liquid chromatography (HPLC), using a Variant machine (Biorad, Hercules, CA); ); intra- and inter-assay coefficients of variation are respectively lower than 0.6% and 1.6%. Linearity is excellent from 3.2% (11 mmol/mol) to 18.3% (177 mmol/mol).

measured by serum 25(OH)D assay, using an immunochemiluminescence (CLIA) method (DiaSorin Liaison® Test, Stillwater MN-USA); the coefficient of inter-individual variability of the method (CVa%) was 10%

AA, EPA, DHA percentages and respective AA/EPA ratio were determined by high-resolution capillary gas chromatography in whole blood using dried blood spots testing

expressed in ng/ml, were measured, on citrate or heparinized plasma, both by chemiluminescent "sandwich" immunoassay (DiaSorin Liaison) and by immunochemiluminescence with automatic analyzer Immulite 2000, Medical Systems with coefficient of variability of 7.40%

a composite index of insulin demand and metabolic control IDAA1c, calculated as HbA1c (%) + 4 insulin dose (UI/kg/24 h), was used. A score <9 meet definition of partial remission and REIS, according with the U.S. Food and Drug Administration, and previous studies in TrialNet

all IPD that underlie results in the publication will be shared

Francesco Cadario, MD

MD Division of Pediatrics

Azienda Ospedaliero Universitaria Maggiore della Carita

University of Eastern Piedmont

A cohort study was performed in 2017, in all T1D patients 1-18 years old with onset in the years 2014-2017. Supplementation with omega3 was proposed to all subjects with onset between 2015-2017. Patients with onset in 2014 were enrolled only as control subjects. The work was performed on retrospectively collected data in medical records for patients with start of the disease in 2014-2016. Patients enrolled since 2017 have been studied prospectively.

juglans ailantifolia/caureja

Omega-3 and Vitamin D Supplements in Childhood T1D

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne